Halozyme Therapeutics (NASDAQ:HALO) Releases FY25 Earnings Guidance

by · The Markets Daily

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $4.95-$5.35 for the period, compared to the consensus estimate of $4.83. The company issued revenue guidance of $1.150-$1.225 billion, compared to the consensus revenue estimate of $1.16 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Halozyme Therapeutics Stock Up 5.0 %

Shares of HALO stock opened at $53.76 on Friday. Halozyme Therapeutics has a 12 month low of $33.15 and a 12 month high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm has a market cap of $6.84 billion, a PE ratio of 17.80, a price-to-earnings-growth ratio of 0.44 and a beta of 1.24. The stock has a 50 day moving average of $50.16 and a 200-day moving average of $54.00.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. HC Wainwright reiterated a “buy” rating and set a $68.00 price target on shares of Halozyme Therapeutics in a research note on Monday, December 30th. Piper Sandler increased their price objective on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. Finally, JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Read Our Latest Stock Analysis on HALO

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total transaction of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $9,254,244.56. This represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.70% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Articles